By: Patient Power
With support from: Brandcast Health
By: AstraZeneca
With support from: Atlantis Healthcare
By: Besins Healthcare
With support from: VCCP Health
By: MSD
With support from: GCI Health
By: Sanofi Genzyme
With support from: Havas Life Medicom
By: Spirit Healthcare
By: AstraZeneca
With support from: Atlantis Healthcare
Acute coronary syndrome (ACS) is a set of life-threatening heart conditions including heart attack and unstable angina for which patients take a range of medications. Treatment adherence is poor, even though the consequences of non-adherence can lead to increased risk of heart attack and mortality. In Abu Dhabi, non-adherence is particularly prominent with persistence rates to OAP medication of just 35% after twelve months. ‘Life After Heart Attack’ (LAHA) a free, multi-channel support programme, was developed for patients with ACS in the United Arab Emirates. LAHA has positively impacted treatment persistence (99% at 3 months; 95% at 6 months and 83% at 12 months post-enrolment), patient beliefs and lifestyle changes.
We liked the visualisation of the results within this well-executed initiative. It had demonstrable outcomes, in terms of belief, lifestyle changes and persistence, and gained excellent feedback from local cardiologists.
Entry deadline | 26 August 2022 |
Extended entry deadline | 2 September 2022* *additional fee applies |
Judging Day | 6 October 2022 |
Company/Team of the Year Interviews | 21 October 2022 |
PMEA Event | 23 November 2022 |